GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (LTS:0VRQ) » Definitions » FFO

CRISPR Therapeutics AG (LTS:0VRQ) FFO


View and export this data going back to 2018. Start your Free Trial

What is CRISPR Therapeutics AG FFO?

FFO (Funds from operations) only applies to REITs.


CRISPR Therapeutics AG (LTS:0VRQ) Business Description

Traded in Other Exchanges
Address
Baarerstrasse 14, Zug, CHE, CH-6300
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.